Item 7.01 Regulation FD Disclosure.

On June 23, 2020, Marker Therapeutics, Inc. (the "Company") announced that it has received approval from the United States Adopted Names Council for the use of "zelenoleucel" as the nonproprietary (generic) name for MT-401. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 of this Current Report on 8-K (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits.



Exhibit No. Description

99.1 Press release, dated June 23, 2020

© Edgar Online, source Glimpses